Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04561492
PHASE2

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Sponsor: Nantes University Hospital

View on ClinicalTrials.gov

Summary

The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.

Official title: Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2021-09-21

Completion Date

2030-05-21

Last Updated

2025-12-08

Healthy Volunteers

No

Interventions

DRUG

[68Ga]Ga-PentixaFor

Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor

Locations (5)

CHU Bordeaux

Bordeaux, France

CHU Lille

Lille, France

HCL

Lyon, France

Nantes UH

Nantes, France

APHP - Site Tenon

Paris, France